NCT01466335View on ClinicalTrials.gov

An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

39

Participants

Timeline

Start Date

October 27, 2011

Primary Completion Date

March 5, 2012

Study Completion Date

March 5, 2012

Conditions

Bone Marrow Transplantation

Interventions

DRUG

Ronacaleret (100mg tablet)

100mg tablet

DRUG

Placebo

matching placebo tablet

Trial Locations (1)

14202

GSK Investigational Site, Buffalo

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01466335 - An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers | Biotech Hunter | Biotech Hunter